Evidence map›Paper›PMID 35488301›Full record

ArticleJournal of neuroinflammation2022

Macrophage-based delivery of interleukin-13 improves functional and histopathological outcomes following spinal cord injury.

Jana Van Broeckhoven, Céline Erens, Daniela Sommer, Elle Scheijen, Selien Sanchez, Pia M Vidal, Dearbhaile Dooley, Elise Van Breedam, Alessandra Quarta, Peter Ponsaerts and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Forced polarisation of microglia by IL-13 is modified by inflammatory and microenvironmental context.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 5 countries.

Jana Van BroeckhovenDepartment of Immunology and Infection, Biomedical Research Institute, Hasselt University, 3590, Diepenbeek, Belgium.
Céline ErensDepartment of Immunology and Infection, Biomedical Research Institute, Hasselt University, 3590, Diepenbeek, Belgium.
Daniela SommerDepartment of Immunology and Infection, Biomedical Research Institute, Hasselt University, 3590, Diepenbeek, Belgium.
Elle ScheijenDepartment of Neurosciences, Biomedical Research Institute, Hasselt University, 3590, Diepenbeek, Belgium.
Selien SanchezDepartment of Immunology and Infection, Biomedical Research Institute, Hasselt University, 3590, Diepenbeek, Belgium.
Pia M VidalNeuroimmunology and Regeneration of the Central Nervous System Unit, Biomedical Science Research Laboratory, Basic Sciences Department, Faculty of Medicine, Universidad Católica de la Santísima Concepción, 4090541, Concepción, Chile.
Dearbhaile DooleySchool of Medicine, Health Sciences Centre, University College Dublin, Belfield, Dublin 4, Ireland.
Elise Van BreedamLaboratory of Experimental Hematology, University of Antwerp, 2610, Wilrijk, Belgium.
Alessandra QuartaLaboratory of Experimental Hematology, University of Antwerp, 2610, Wilrijk, Belgium.
Peter PonsaertsLaboratory of Experimental Hematology, University of Antwerp, 2610, Wilrijk, Belgium.
Sven Hendrix *Department of Immunology and Infection, Biomedical Research Institute, Hasselt University, 3590, Diepenbeek, Belgium. sven.hendrix@medicalschool-hamburg.de.ORCID http://orcid.org/0000-0003-2344-7369
Stefanie Lemmens *Department of Immunology and Infection, Biomedical Research Institute, Hasselt University, 3590, Diepenbeek, Belgium.
Hasselt University · BEUniversity of Antwerp · BEMSH Medical School Hamburg – University of Applied Sciences and Medical University · DEUniversidad Católica de la Santísima Concepción · CLUniversity College Dublin · IE

Funding

fonds wetenschappelijk onderzoek G067715Nfonds wetenschappelijk onderzoek G091518Nfonds wetenschappelijk onderzoek G0C2120N
6 · The paper itself

Abstract

backgroundSpinal cord injury (SCI) elicits a robust neuroinflammatory reaction which, in turn, exacerbates the initial mechanical damage. Pivotal players orchestrating this response are macrophages (Mφs) and microglia. After SCI, the inflammatory environment is dominated by pro-inflammatory Mφs/microglia, which contribute to secondary cell death and prevent regeneration. Therefore, reprogramming Mφ/microglia towards a more anti-inflammatory and potentially neuroprotective phenotype has gained substantial therapeutic interest in recent years. Interleukin-13 (IL-13) is a potent inducer of such an anti-inflammatory phenotype. In this study, we used genetically modified Mφs as carriers to continuously secrete IL-13 (IL-13 Mφs) at the lesion site.

methodsMφs were genetically modified to secrete IL-13 (IL-13 Mφs) and were phenotypically characterized using qPCR, western blot, and ELISA. To analyze the therapeutic potential, the IL-13 Mφs were intraspinally injected at the perilesional area after hemisection SCI in female mice. Functional recovery and histopathological improvements were evaluated using the Basso Mouse Scale score and immunohistochemistry. Neuroprotective effects of IL-13 were investigated using different cell viability assays in murine and human neuroblastoma cell lines, human neurospheroids, as well as murine organotypic brain slice cultures.

resultsIn contrast to Mφs prestimulated with recombinant IL-13, perilesional transplantation of IL-13 Mφs promoted functional recovery following SCI in mice. This improvement was accompanied by reduced lesion size and demyelinated area. The local anti-inflammatory shift induced by IL-13 Mφs resulted in reduced neuronal death and fewer contacts between dystrophic axons and Mφs/microglia, suggesting suppression of axonal dieback. Using IL-4Rα-deficient mice, we show that IL-13 signaling is required for these beneficial effects. Whereas direct neuroprotective effects of IL-13 on murine and human neuroblastoma cell lines or human neurospheroid cultures were absent, IL-13 rescued murine organotypic brain slices from cell death, probably by indirectly modulating the Mφ/microglia responses.

conclusionsCollectively, our data suggest that the IL-13-induced anti-inflammatory Mφ/microglia phenotype can preserve neuronal tissue and ameliorate axonal dieback, thereby promoting recovery after SCI.

Indexed as

NeuroblastomaNeuroprotective AgentsSpinal Cord InjuriesAnimalsFemaleHumansInterleukin-13MacrophagesMiceInterleukin-13Neuroprotective AgentsCNS traumaImmunomodulationInterleukin-13MacrophagesNeuroinflammationNeurospheroids

Identifiers

PMID35488301
PMCPMC9052547
OpenAlexW4225092886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.